PIE II: Pharmacological Intervention in the Elderly II

Clinical Trial ID NCT00123955

PubWeight™ 1.90‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00123955

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 29.32
2 Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002 4.06
3 Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991 3.30
4 Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001 2.93
5 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000 2.15
6 Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension 2012 1.04
7 Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002 0.96
8 Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail 2009 0.94
Next 100